1-year outcomes of single bolus r-SAK before primary PCI for STEMI: The follow-up of OPTIMA-5

The OPTIMA-5 study demonstrated that a single bolus of half-dose recombinant staphylokinase (r-SAK) before primary percutaneous coronary intervention (PCI) significantly improved the patency of infarct related artery in patients with ST-elevation myocardial infarction (STEMI) expected to undergo PCI within 120 minutes. This study aimed to investigate the 1-year clinical outcome and the effect of the r-SAK antibody on a second r-SAK thrombolysis in OPTIMA-5 patients. The clinical outcome was major adverse cardiovascular events (MACE) within 360 days. Patients’ r-SAK antibodies were determined on days 90 ±7, 180 ±7, and 360 ±14 after thrombolysis, and in-vitro r-SAK antibody neutralization experiments were performed to explore an optimal interval for a second r-SAK thrombolysis. Results showed that the MACE incidence was numerically lower in r-SAK group compared with normal saline (NS) group (14.0% vs. 20.0%, HR 0.67, 95% CI: 0.34- 1.32; log-rank P=0.245). The r-SAK antibody levels in r-SAK group decreased by time, but kept significantly higher than those in NS group on days 90 ±7 (2.96 ±0.68 vs. 0.22 ±0.53, P<0.001), 180 ±7 (2.19 ±0.74 vs. 0.44 ±0.65, P<0.001) and 360 ±14 (1.73 ±0.97 vs. 0.37 ±0.71, P<0.001). The in-vitro r-SAK antibody neutralization experiments illustrated that the thrombolysis rate decreased exponentially as the antibody titer increased from 1.90 to 2.20 (67.80 ±14.19% vs. 44.32 ±21.54%, P<0.0001). Therefore, for STEMI patients expected to undergo PCI within 120 minutes, a single bolus of half-dose r-SAK before primary PCI may reduce 1-year MACE risk. The r-SAK antibody lasts over 1 year, and a second r-SAK thrombolysis may not be indicated until 1 year after the first r-SAK thrombolysis if necessary.